Research Article

Administration of PDE4 Inhibitors Suppressed the Pannus-Like Inflammation by Inhibition of Cytokine Production by Macrophages and Synovial Fibroblast Proliferation

Katsuya Kobayashi, Toshio Suda, Haruhiko Manabe, and Ichiro Miki

Pharmacological Research Laboratories, Pharmaceutical Research Center, Kyowa Hakko Kogyo Co., Ltd., 1188 Shimotogari, Nagaizumi-Cho, Sunto-Gun, Shizuoka-Ken 411-8731, Japan

Correspondence should be addressed to Ichiro Miki, ichiro.miki@Kyowa.co.jp

Received 18 May 2007; Revised 10 August 2007; Accepted 3 September 2007

A marked proliferation of synovial fibroblasts in joints leads to pannus formation in rheumatoid arthritis (RA). Various kinds of cytokines are produced in the pannus. The purpose of this study is to elucidate the effects of phosphodiesterase 4 (PDE4) inhibitors in a new animal model for the evaluation of pannus formation and cytokine production in the pannus. Mice sensitized with methylated bovine serum albumin (mBSA) were challenged by subcutaneous implantation of a membrane filter soaked in mBSA solution in the back of the mice. Drugs were orally administered for 10 days. The granuloma formed around the filter was collected on day 11. It was chopped into pieces and cultured in vitro for 24 hr. The cytokines were measured in the supernatants. The type of cytokines produced in the granuloma was quite similar to those produced in pannus in RA. Both PDE4 inhibitors, KF66490 and SB207499, suppressed the production of IL-1β, TNF-α, and IL-12, and the increase in myeloperoxidase activity, a marker enzyme for neutrophils and hydroxyproline content. Compared to leflunomide, PDE4 inhibitors more strongly suppressed IL-12 production and the increase in myeloperoxidase activity. PDE4 inhibitors also inhibited lipopolysaccharide-induced TNF-α and IL-12 production from thioglycolate-induced murine peritoneal macrophages and the proliferation of rat synovial fibroblasts. These results indicate this model makes it easy to evaluate the effect of drugs on various cytokine productions in a granuloma without any purification step and may be a relevant model for evaluating novel antirheumatic drugs on pannus formation in RA. PDE4 inhibitors could have therapeutic effects on pannus formation in RA by inhibition of cytokine production by macrophages and synovial fibroblast proliferation.

Copyright © 2007 Katsuya Kobayashi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

1. INTRODUCTION

Rheumatoid arthritis (RA) is a systemic autoimmune disease characterized by the progressive chronic inflammation of multiple joints. The incidence of RA is close to 1% worldwide, but its etiology is not yet known. The search for therapeutic agents for RA is being conducted mainly using collagen-induced arthritis and adjuvant-induced arthritis [1, 2]. In the development of arthritis, pannus formation is the critical step in the destruction of cartilage and bones. Pannus is a proliferative granulomatous tissue, mainly composed of macrophages and fibroblast-like synoviocytes. Pannus contains numerous cytokines and proteases inside. Although collagen-induced arthritis and adjuvant-induced arthritis models are very useful for screening candidates for novel antirheumatic drugs, it is not easy to elucidate the effects of candidates on the pannus formation. Also, quantitative analysis of cytokine levels is required to elucidate the role of cytokines in the pathogenesis of pannus formation. However, many steps are needed to measure cytokines in the pannus in arthritis models. For example, the ankle joints have to be removed, frozen in liquid nitrogen, crushed, homogenated, and finally cytokines are assayed by enzyme-linked immunosorbent assay (ELISA) in the supernatants [3]. Therefore, an inflammatory model is needed to simply evaluate the effects of drugs on pannus formation and cytokine production in pannus.

There is only a few animal models available for the evaluation of antiarthritic drugs on pannus formation. One of the granuloma models, a cotton pellet-induced granuloma model, is widely used as a model for pannus formation [4].
The problem with this model is, however, that the granuloma is formed by a foreign-body-dependent granuloma reaction. The mechanism of pannus formation has not been fully proven yet, but T cells seem to be involved in pannus formation [5]. Another granuloma model, delayed-type hypersensitivity (DTH) granuloma, has been reported to be antigen-specific and T cell-mediated [6–8]. Histological features of the lesions from DTH granuloma revealed the evolution of DTH into a chronic granulomatous reaction, as shown by the following changes: fibrin deposition, vasculitis, mononuclear cell infiltration/proliferation, and angiogenesis [6]. They reported that DTH granuloma represented a relevant model for probing pathogenic mechanisms and potential therapeutics for RA. In this study, we modified the DTH granuloma model so that we could easily measure cytokine production from the granulomatous tissue. The granuloma was induced by a subcutaneous implantation of a thin membrane filter soaked in methylated bovine serum albumin (mBSA) solution into the back of the mice previously sensitized with mBSA. For cytokine determination, the granuloma was collected from the back of the mice on the indicated days and incubated in culture medium for 24 hours in vitro, and the cytokines were measured in the supernatants.

Phosphodiesterase 4 (PDE4) inhibitors are key enzymes that degrade cAMP and play an important role in inflammatory and immune reactions [9]. The prevention of cAMP degradation by PDE4 inhibitors elevates the level of cAMP in the cells followed by suppression of inflammation and immune responses. Rolipram is a well-known PDE4 inhibitor that reduces the inflammatory responses in several rodent models, including carrageenan-induced edema [10], adjuvant arthritis [10, 11], antigen-induced airway inflammation [12, 13], lipopolysaccharide (LPS)-induced lung inflammation [14] and collagen-induced arthritis [15]. Inhibitions of leukotriene B4 (LTB4), interferon-γ (IFN-γ), tumor necrosis factor-α (TNF-α), interleukin-4 (IL-4), and IL-5 are all potential mechanisms by which the anti-inflammatory effects of rolipram are mediated [16]. These results suggest that PDE4 inhibitors may be therapeutic agents for various diseases such as asthma, chronic obstructive pulmonary disease, and rheumatoid arthritis. In this study, we evaluated PDE4 inhibitors, KF66490 and SB207499 [17], in the mouse pannus model and compared the effects of the PDE4 inhibitors with those of typical antirheumatic drugs leflunomide, prednisolone, and methotrexate.

2. MATERIAL AND METHODS

2.1. Animals

Male, 6-week-old BALB/c mice were purchased from Charles River Japan (Kanagawa, Japan) and maintained at a temperature of 22 ± 3°C and a humidity of 50 ± 20%. Food and water were provided ad libitum. The study protocol for the animal experiment was approved by the Animal Care Committee of Kyowa Hakko Kogyo Co., Ltd.

2.2. Reagents

Leflunomide, KF66490 and SB207499 were synthesized in our institute. Methotrexate (MTX) was purchased from Lederle Japan, Ltd. (Tokyo, Japan). Prednisolone, diclofenac sodium and methylated bovine serum albumin (mBSA) were purchased from Sigma-Aldrich Japan (Tokyo, Japan). Sources of other chemicals were as follows: Freund’s complete adjuvant (Difco, Detroit, Mich, USA); myeloperoxidase (Sigma-Aldrich Japan), hexadecyltrimethylammonium bromide (Sigma-Aldrich Japan); ELISA kits for each mouse cytokine: IL-6 and IL-1β (BioSource International, Camarillo, Calif, USA), TNF-α (R&D Systems, Minneapolis, MN, USA), IFN-γ (PIERCE, Rockford, Ill, USA), IL-4 (BD Bioscience, San Diego, Calif, USA), IL-10 (BD Bioscience), IL-12 (Genzyme, Cambridge, Mass, USA); RPMI 1640 tissue culture medium (Sigma-Aldrich); fetal bovine serum (Intergen, Purchase, NY, USA); penicillin-streptomycin (Life Technologies, Rockville, Md, USA); and 2-mercaptoethanol (Wako Pure Chemical).

2.3. Induction of granuloma

Granuloma was induced according to Dunn et al. [6] with a slight modification. Methylated BSA (mBSA: 4 mg/mL in saline) was emulsified in an equal volume of Freund’s complete adjuvant. The emulsion (0.1 mL containing 200 µg mBSA) was injected intradermally on the back of the mice. Seven days later, the same treatment was repeated. Two weeks after the last sensitization, a membrane filter (13 mm diameter, 0.05 mm thickness, Millipore Japan, Tokyo, Japan) which had been soaked in mBSA solution (4 mg/mL in saline) for 60 minutes was subcutaneously implanted in the dorsum of the mice (day 0). The wound was closed with 9 mm autoclips (Clay Adams, Parsippany, NJ).

2.4. Measurement of cytokines and anti-mBSA antibodies in the culture supernatants

Mice were killed by CO₂ asphyxiation. The granuloma formed around the filter was collected from the back of the mice and chopped into pieces in 4 mL of 1640 tissue culture medium supplemented with 10% heat-inactivated fetal bovine serum (FBS), 50 unit/mL penicillin-50 µg/mL streptomycin, and 50 µmol/L 2-mercaptoethanol. The tissue was cultured for 24 hours at 37°C. Cytokines were measured by ELISA kits in the supernatants. Anti-mBSA specific IgG1 and IgM antibodies in the supernatants were measured by ELISA [18], and the results were expressed as the absorbance at 450 nm.

2.5. Measurement of myeloperoxidase activity and hydroxyproline content in the granuloma

Myeloperoxidase activity was measured using a specific substrate in the mixture of the culture medium and the granulomatous tissue. Briefly, the chopped tissues and the remaining supernatants (total 3.2 mL) were mixed with 0.16 mL of potassium phosphate buffer (0.5 mol/L, pH 6.0) and 0.16 mL.
hexadecyltrimethylammonium bromide solution (10%) and vigorously vortexed. Samples were incubated for 20 minutes at 4°C. After centrifugation (1800 g, 20 minutes), the enzyme activity in the supernatant was measured [19]. The remaining tissue and the supernatant were mixed with an equal amount (3.3 mL) of HCl (12 mol/L) and incubated for 15 hours at 110°C for the measurement of hydroxyproline content according to the procedure of Jakubzick [20]. Data were expressed as total enzyme activity or total hydroxyproline content in the granuloma.

2.6. Time course analysis of the murine pannus model

The granuloma was collected on days 1, 3, 6, 10, 15, 22, and 30 and cultured in vitro. A saline-soaked filter was implanted in the back of the mice as a negative control group (Saline group).

2.7. Evaluation of antirheumatic drugs and PDE4 inhibitors

All drugs were suspended in 0.5% methylcellulose in distilled water and orally administered once a day from day 0 to 10. Control group was treated with 0.5% methylcellulose (Vehicle group). The granuloma was collected on day 11.

2.8. Thioglycolate-elicited peritoneal macrophages

Male BALB/c mice (8–10 weeks old) were injected intraperitoneally with 1 ml of 3% (w/vol) thioglycolate broth (Wako Pure Chemical). Four days later, cells were harvested by peritoneal lavage with RPMI 1640 medium. The cells were washed twice, and 2.5 × 10⁶ peritoneal cells (for TNF-α production) or 2 × 10⁶ peritoneal cells (for IL-12 production) per 0.2 mL in the same medium containing 10% FBS were then added to each well of 96-well plates. The cells were allowed to adhere to well at 37°C in a humidified 5% CO₂ atmosphere, and after 2 hours, nonadherent cells were removed by gentle washing. Adherent cells were used as thioglycolate-elicited peritoneal macrophages. Adherent cells were stimulated with 1 μg/mL of LPS for 6.5 hours (for TNF-α) or 24 hours (for IL-12) at 37°C. After the incubation, the supernatant was collected. Cytokines were measured by ELISA kits in the supernatants.

2.9. Culture of rat synovial fibroblasts

Surface parts of synovial tissues were isolated from knee joints of female, 8-week-old Lewis rats (Charles River Japan), followed by washing with phosphate-buffered saline (PBS) and subsequent digestion with 0.2% collagenase in RPMI 1640 medium at 37°C for 2 hours. Synovial tissues were then treated with 0.2% collagenase and 0.25% trypsin at 37°C for 2 hours. Cells were collected in RPMI 1640 containing 10% FBS and antibiotics, and then centrifuged at 500 x g for 5 minutes. The pellets were suspended in RPMI 1640 containing 10% FBS. Cells were used for experiments after three to eight passages as synovial fibroblasts.

2.10. Proliferation of rat synovial fibroblasts

Synovial fibroblasts (1 × 10⁵ cells) suspended in 200 μL of RPMI 1640 medium supplemented with 1% FBS, 0.9% BSA and antibiotics were precultured for 24 hours at 37°C. After the preculture, the culture medium was changed to RPMI 1640 medium supplemented with 10% FBS and cells were cultured in the presence or absence of compounds for 48 hours at 37°C followed by 24 hours culture in the presence of 1.25 μCi/mL of [methyl-³H] thymidine. In the case of methotrexate and leflunomide, 1.25 μCi/mL of [³H] deoxyuridine was also used instead of [methyl-³H] thymidine [21, 22]. The incorporation of [³H] thymidine or [³H] deoxyuridine was counted by a liquid scintillation counter.

2.11. Statistical analyses

The Student’s t test or Aspin-Welch test following an F-test was used for analysis of differences between the two groups. Multiple comparisons among treatment groups were performed by 1-way ANOVA followed by the Dunnett test or Kruskal-Wallis followed by the Steel test. P values less than .05 were considered to be statistically significant.

3. RESULTS

3.1. Time course analysis of the murine pannus model

The granulomas collected on the indicated days were chopped into pieces in culture medium. Cytokine concentrations and anti-mBSA specific IgG1 and IgM antibody titer in the supernatants were measured after 24-hour incubation without any manipulation to extract cytokines from the granulomatous tissues (Figure 1). The concentration of IL-1β peaked on day 10 and then gradually decreased in the mBSA-treated group (Figure 1(a)). TNF-α and IL-6 were both released on day 1, transiently decreased on day 3, and were constantly released until day 30 (Figures 1(b), 1(e)). IL-12 release peaked on day 6, while IFN-γ was slightly delayed and peaked on day 10 (Figure 1(d) and data not shown). IL-4 and IL-10 were significantly increased only on day 1 (data not shown). Anti-mBSA specific IgG1 antibody concentration was significantly increased from day 6 and sustained until day 22 (data not shown). Anti-mBSA specific IgM antibody concentration was significantly increased from day 1 and peaked on day 15 (data not shown). Myeloperoxidase (MPO) activity, a marker enzyme for neutrophil infiltration in the mixture of the culture medium and the granuloma, was constantly high in the mBSA-treated group (Figure 1(e)). Hydroxyproline content, a marker of fibrosis, increased with time and peaked on day 15 in the granuloma (Figure 1(f)).

3.2. Evaluation of antirheumatic drugs and PDE4 inhibitors

Drugs were orally administered for 10 days from the day of the implantation of mBSA-soaked filter in the back of the mice. IL-1β production from the granuloma was suppressed by both PDE4 inhibitors, KF66490 and SB207499, leflunomide, and prednisolone, but not by methotrexate.
Figure 1: Time course of cytokine productions, myeloperoxidase (MPO) activity, and hydroxyproline content in the mBSA-induced granulomatous tissue. Mice sensitized with mBSA were challenged by subcutaneous implantation of a membrane filter soaked in mBSA solution in the back of the mice on day 0. Granuloma was collected on the indicated days and cultured in vitro for 24 hr. Cytokines were measured in the supernatants. MPO activity and hydroxyproline content were measured in a mixture of the culture medium and the granuloma. IL-1β (a), TNF-α (b), IL-6 (c), IL-12 (d), MPO activity (e), and hydroxyproline content (f). Results are shown as the mean ± SE of 4 to 6 mice. #: P < .05, ##: P < .01, ###: P < .001 (The Student’s t test), ∗: P < .05, ∗∗: P < .01, ∗∗∗: P < .001 (Aspin-Welch test). Representative data from three independent experiments are shown.

3.3. Cytokine production from thioglycolate-elicited peritoneal macrophages

To evaluate the effects of PDE4 inhibitors on proinflammatory cytokine production, LPS-stimulated TNF-α and IL-12 production from thioglycolate-elicited peritoneal macrophages were conducted in vitro. Both PDE4 inhibitors suppressed LPS-stimulated TNF-α and IL-12 production with IC_{50} values of 0.88 and 4.2 μmol/L (KF66490), and 0.12 and 0.52 μmol/L (SB207499), respectively (Table 3).

3.4. Proliferation of rat synovial fibroblasts

To evaluate the antiproliferative activity of PDE4 inhibitors and antirheumatic drugs on fibroblasts, the proliferation of rat synovial fibroblasts was conducted. KF66490 and SB207499 inhibited serum-stimulated proliferation of rat synovial fibroblasts with an IC_{50} values of 9.2 and 3.1 μmol/L, respectively (Table 4). Leflunomide did not inhibit it even at
100 μmol/L. Prednisolone and methotrexate inhibited it with IC_{50} values of 0.070 and 0.013 μmol/L, respectively.

4. DISCUSSION

We have shown that this pannus model makes it much easier to determine a variety of cytokines produced in the granuloma than the previous methods which needs many steps to extract cytokines from tissue, and the type of cytokines is very similar to that reported to be increased in the pannus in the patients with RA. Antirheumatic drugs suppressed these cytokine productions and hydroxyproline contents. These results suggest that this model could be a relevant model for evaluation of pannus formation in patients with RA. Both PDE4 inhibitors, KF66490 and SB207499, showed an effect comparable to those of antirheumatic drugs in this model; and also, PDE4 inhibitors inhibited lipopolysaccharide-induced TNF-α and IL-12 production from thioglycolate-induced murine peritoneal macrophages and the proliferation of rat synovial fibroblasts. Therefore, PDE4 inhibitors could have therapeutic effects on pannus formation in RA by inhibition of cytokine production by macrophages and synovial fibroblast proliferation.

There was no report on the measurement of cytokines in delayed-type hypersensitivity granuloma. We compared cytokine concentrations between in-tissue homogenate samples and in-culture supernatants of the granuloma. However, a marked variability of cytokine concentrations was observed in the case of using homogenate samples (data not shown). The new method showed that the variation was relatively small and could be useful for the measurement of cytokine productions from granulomatous tissues.

A broad array of macrophages and fibroblast cytokines, including TNF-α, IL-1, IL-6, and IL-12 are produced by the
rheumatoid synovium in the pannus [23–25]. TNF-α, IL-1β, and IL-6 have been reported to play a pivotal role in the pathogenic mechanisms of RA [26–28]. In this study, chronic production of TNF-α, IL-1β, IL-6, and IL-12 was observed. These observations suggest that this pannus model is useful for evaluating the effects of drugs on the production of cytokines involved in the pathogenic mechanisms of RA. PDE4 inhibitors suppressed these all cytokine production in vivo and TNF-α and IL-12 production in vitro. These results suggest that PDE4 inhibitors directly suppress the production of TNF-α and IL-12, and indirectly suppress the production of IL-1β and IL-6 which are possibly induced by TNF-α stimulation. Because it has been reported that TNF-α transgenic mice develop arthritis with enhanced production of TNF-α, IL-1, and IL-6 [29], which means TNF-α is the major dominant regulator of IL-1β and IL-6 [30]. Additional explanation of antipannus forming effects of PDE4 inhibitors is the inhibition of fibroblast proliferation. The maximum plasma concentration of SB207499 was about 19 μmol/L at the maximum dose used in this study (30 mg/kg p.o.) [31]. Therefore, the inhibition of fibroblast proliferation is considered to be involved in antipannus forming effects of PDE4 inhibitors.

### Table 1: Summary of cytokine productions.

| Drug      | Dose (mg/kg) | TNF-α (% inhibition) | IL-1β (% inhibition) | IL-6 (%) | IL-12 (%) |
|-----------|--------------|-----------------------|----------------------|---------|----------|
| KF66490   | 3            | 50**                  | 33                   | −8      | 35**     |
|           | 10           | 61**                  | 60*                  | −41*    | 40**     |
|           | 30           | 55**                  | 80*                  | 30      | 59***    |
|           | 3            | 41*                   | 39                   | 14      | 25       |
| SB207499  | 10           | 56**                  | 65**                 | 7       | 51***    |
|           | 30           | 72***                 | 86***                | 47*     | 72***    |
| Leflunomide| 3            | 67**                  | 29                   | 9       | −4       |
|           | 10           | 72**                  | 48*                  | 9       | 55*      |
|           | 30           | 111***                | 71**                 | 44**    | 43       |
| Prednisolone| 10         | 86***                 | 60                   | 65      | 87*      |
|           | 30           | 107***                | 102**                | 93*     | 103***   |
| Methotrexate| 3           | 63                   | −68                  | 41*     | −17      |
|           | 30           | 83**                 | 37                   | 53**    | 10       |
| Diclofenac| 1            | −68*                  | −4                   | 26      | −37      |
|           | 3            | −77*                  | −9                   | 51*     | −92*     |

*P < .05, **P < .01, ***P < .001. Representative data from two or three independent experiments are shown.

### Table 2: Summary of MPO activity, hydroxyproline content, anti-mBSA IgG1, and anti-mBSA IgM antibody production.

| Drug      | Dose (mg/kg) | MPO | Hydroxyproline (% inhibition) | Anti-mBSA IgG1 antibody (% inhibition) | Anti-mBSA IgM antibody (%) |
|-----------|--------------|-----|-------------------------------|----------------------------------------|---------------------------|
| KF66490   | 3            | 22  | 58*                           | 34                                     | 9                         |
|           | 10           | 61* | 37                            | 39                                     | 33                        |
|           | 30           | 67* | 75**                          | 79*                                    | 34                        |
|           | 3            | 50* | 61**                          | 38                                     | 11                        |
| SB207499  | 10           | 51* | 47*                           | 81*                                    | 39                        |
|           | 30           | 83*** | 78***                         | 61                                     | 34                        |
|           | 3            | −20 | 46*                           | 42                                     | 34                        |
| Leflunomide| 10           | 36  | 62**                          | 95*                                    | 86*                       |
|           | 30           | 80** | 72***                         | 104*                                   | 100*                      |
|           | 3            | 60  | 79**                          | 68*                                    | 45                        |
| Prednisolone| 10        | 9   | 81**                          | 75*                                    | 55                        |
|           | 30           | 99* | 100***                        | 90*                                    | 67                        |
| Methotrexate| 3           | −22 | 9                             | 47                                     | 40                        |
|           | 10           | 52  | 25                            | 87**                                   | 91*                       |
|           | 1            | −29 | 27                            | 17                                     | −86                       |
|           | 3            | −66 | −18                           | 20                                     | −120                      |

*P < .05, **P < .01, ***P < .001. Representative data from two or three independent experiments are shown.
Interestingly, it has been reported that den-

Table 3: IC\textsubscript{50} values of KF66490 and SB207499 on LPS-
induced cytokine production from thioglycolate-elicted peritoneal
macrophages.

| Drug     | IC\textsubscript{50} (μmol/L) |
|----------|-----------------------------|
| KF66490  | 0.88                        |
| SB207499 | 0.12                        |

Thioglycolate-induced adherent peritoneal cells were stimulated with
1 μg/mL of LPS in the presence or absence of compounds for 6.5 h (for TNF-
\(\alpha\)) or 24 h (for IL-12) at 37°C. After the incubation, cytokines were mea-
sured by ELISA kits in the supernatants. Data are mean value of two or three
independent experiments.

Table 4: IC\textsubscript{50} values of various drugs on serum-induced prolifera-
tion of rat synovial fibroblasts.

| Drug        | IC\textsubscript{50} (μmol/L) |
|-------------|-----------------------------|
| KF66490     | 9.2                         |
| SB207499    | 3.1                         |
| Leflunomide | >100                        |
| Prednisolone| 0.070                       |
| Methotrexate| 0.013                       |

Rat synovial fibroblasts were pre-cultured in culture medium supplemented
with 1% FBS for 24 h at 37°C. After the preculture, cells were stimulated by
10% FBS in the presence or absence of compounds for 48 h at 37°C followed
by 24 h culture in the presence of 1.25 μg/ml of [methyl\(^{3}\)H] thymidine or
[6\(^{-}\)H] deoxyuridine. The incorporation of \[^{3}\]H thymidine or \[^{6}\]H
deoxyuridine was counted by a liquid scintillation counter. Data are mean
value of three or four separate determinations.

Some autoantibody levels in the synovial fluid are specif-
ically related to the pathogenesis of RA [32, 33]. PDE4 in-
hibitors suppressed IgG\(_1\) but not IgM production in the pan-
nus supernatants. This finding conflicts with previous re-
ports that PDE4 inhibitors inhibit IgG\(_1\) or IgG\(_2\) antibody
production in vivo [34, 35], but they did not measure the
antibody levels in the inflammatory sites. These results sug-
gest that PDE4 inhibitors inhibit antibody production in the
inflammatory sites. It is not known exactly why PDE4 in-
hibitors suppressed the IgG\(_1\) production; but in our model,
IL-4 production on day 1 was completely inhibited by both
PDE4 inhibitors (85 or 83% inhibition at 10 or 30 mg/kg of
KF66490 and 55 or 103% inhibition at 10 or 30 mg/kg of
SB207499). IL-4 is known to promote the proliferation and
differentiation of activated B-cells. Therefore, the suppres-
sion of IL-4 production by PDE4 inhibitors may have had
some inhibitory effects on B cells.

It has been reported that PDE4 inhibitors suppress both
Th\(_1\) and Th\(_2\) cytokine production from stimulated T cells in
vitro [36, 37]. However, the inhibition is partial. There-
fore, we believe that the suppression of T cell function is less
involved in antinpanus effects of PDE4 inhibitors because
no obvious inhibition of IFN-\(\gamma\) production was observed in
our model (data not shown); and also, we did not find
any effect on IFN-\(\gamma\) and IL-6 production from concanavalin.
A stimulated murine splenic T cells up to 10 μmol/L (data
not shown). Interestingly, it has been reported that den-

reduce the development of IFN-\(\gamma\)-expressing effector T cells
[38]. Therefore, PDE4 inhibitors seem to affect the develop-
ment of Th\(_1\) cells in vitro; but as mentioned above, IL-
4 production was completely inhibited by PDE4 inhibitors
in our model. The suppression of IL-4 production by PDE4
inhibitors might have had an impact on Th\(_1\)/Th\(_2\) balance.
Taken together, although PDE4 inhibitors preferentially di-
minish Th\(_1\) responses, some effects of PDE4 inhibitors on
Th\(_2\) responses [36, 37] might complicate the in vivo re-
ponses. Consequently, we think the effects of PDE4 in-
hibitors on in vivo Th\(_1\)/Th\(_2\) responses depend on the type
of inflammation.

Recently, IL-17-producing T cells have been classified
as a new effector T-cell subset, termed Th\(_17\), which is dis-
tinct from Th\(_1\), Th\(_2\), and Treg subsets. It is very interest-
ing to examine whether PDE4 inhibitors suppresses the IL-
23 or transforming growth factor (TGF-\(\beta\)) production from
macrophages. IL-23, IL-6, and TGF-\(\beta\) promote the differen-
tiation of Th\(_17\) cells, which are considered to act as the key
effector-cell subset in inflammatory arthritis, at least in ro-
dents [39].

In conclusion, this study provides a unique murine model to easily evaluate the effects of the drugs on the forma-
tion of the granuloma and cytokine production in a granu-
loma. PDE4 inhibitors showed an effect comparable to those
of antirheumatic drugs in this model. The suppression of
TNF-\(\alpha\) and IL-12 production and the inhibition of fibroblast
proliferation were considered to contribute to the antipannus
forming effects of PDE4 inhibitors.

ACKNOWLEDGMENTS

The authors would like to thank to Ms. Eri Okita for their
expert technical assistance and Mr. Koji Yanagawa for syn-
thesis of compounds. They are also grateful to Dr. Mark W
Lethbridge for kind discussion.

REFERENCES

[1] D. E. Trentham, A. S. Townes, and A. H. Kang, “Autoimmunity
to type II collagen: an experimental model of arthritis,” Journal
of Experimental Medicine, vol. 146, no. 3, pp. 857–868, 1977.

[2] K. D. Rainsford, “Adjuvant polyarthritis in rats: is this a sat-
sisfactory model for screening anti-arthritic drugs?” Agents &
Actions, vol. 12, no. 4, pp. 452–458, 1982.

[3] K. Magari, S. Miyata, Y. Ohkubo, and S. Mutoh, “Inflamma-
tory cytokine levels in paw tissues during development of rat
collagen-induced arthritis: effects of FK506, an inhibitor of T
cell activation,” Inflammation Research, vol. 53, no. 9, pp. 469–
474, 2004.

[4] G. Engelhardt, D. Homma, K. Schlegel, R. Uitzmann, and
C. Schnitzler, “Anti-inflammatory, analgesic, antipyretic and
related properties of meloxicam, a new non-steroidal anti-
inflammatory agent with favourable gastrointestinal toler-
ance,” Inflammation Research, vol. 44, no. 10, pp. 423–433,
1995.

[5] C. Vingsbo, P. Sahlin, J. G. Brun, R. Jonsson, T. Saxne,
and R. Holmdahl, “Pristane-induced arthritis in rats: a new
model for rheumatoid arthritis with a chronic disease course
influenced by both major histocompatibility complex and
non-major histocompatibility complex genes,” American Journal of Pathology, vol. 149, no. 5, pp. 1673–1683, 1996.

[6] C. J. Dunn, A. J. Gibbons, and S. K. Miller, “Development of a delayed-type hypersensitivity granuloma model in the mouse for the study of chronic immune-mediated inflammatory disease,” Agents & Actions, vol. 27, no. 3–4, pp. 365–368, 1989.

[7] C. J. Dunn, L. A. Galinet, A. J. Gibbons, and S. K. Shields, “Murine delayed-type hypersensitivity granuloma: an improved model for the identification and evaluation of different classes of anti-arthritis drugs,” International Journal of Immunopharmacology, vol. 12, no. 8, pp. 899–904, 1990.

[8] B. Särmstrand, A.-H. Jansson, G. Matsuveciune, A. Scheynius, S. Pierrou, and H. Bergstrand, “N′,N′-diacetyl-L-cystine—the disulfide dimer of N-acetylcysteine—is a potent modulator of contact sensitivity/delayed type hypersensitivity reactions in rodents,” Journal of Pharmacology and Experimental Therapeutics, vol. 288, no. 3, pp. 1174–1184, 1999.

[9] W. Bäumer, J. Hoppmann, C. Rundfeldt, and M. Kietzmann, “Highly selective phosphodiesterase 4 inhibitors for the treatment of allergic skin diseases and psoriasis,” Inflammation & Allergy - Drug Targets, vol. 6, no. 1, pp. 17–26, 2007.

[10] L. Sekut, D. Yarnall, S. A. Stimpson, et al., “Anti-inflammatory activity of phosphodiesterase (PDE)-IV inhibitors in acute and chronic models of inflammation,” Clinical & Experimental Immunology, vol. 100, no. 1, pp. 126–132, 1995.

[11] J. N. Francischini, C. M. Yokoro, S. Poole, W. L. Tafuri, F. Q. Cunha, and M. M. Teixeira, “Anti-inflammatory and analgesic effects of the phosphodiesterase 4 inhibitor rolipram in a rat model of arthritis,” European Journal of Pharmacology, vol. 399, no. 2-3, pp. 243–249, 2000.

[12] L. Wollin, D. S. Bundschuh, A. Wohlsen, D. Marx, and R. Beume, “Inhibition of airway hyperresponsiveness and pulmonary inflammation by rolufimist and other PDE4 inhibitors,” Pulmonary Pharmacology & Therapeutics, vol. 19, no. 5, pp. 343–352, 2006.

[13] A. Kanehiro, T. Ikemura, M. J. Mäkelä, et al., “Inhibition of phosphodiesterase 4 attenuates airway hyperresponsiveness and airway inflammation in a model of secondary allergen challenge,” American Journal of Respiratory and Critical Care Medicine, vol. 163, no. 1, pp. 173–184, 2001.

[14] F. J. Johnson, L. J. Reynolds, and T. J. Toward, “Elastolytic activity and alveolar epithelial type-1 cell damage after chronic LPS inhalation: effects of dexamethasone and rolipram,” Toxicology and Applied Pharmacology, vol. 207, no. 3, pp. 257–265, 2005.

[15] S. E. Ross, R. O. Williams, L. J. Mason, et al., “Suppression of TNF-α expression, inhibition of Th1 activity, andamelioration of collagen-induced arthritis by rolipram,” Journal of Immunology, vol. 159, no. 12, pp. 6253–6259, 1997.

[16] Z. Huang and J. A. Mancini, “Phosphodiesterase 4 inhibitors for the treatment of asthma and COPD,” Current Medicinal Chemistry, vol. 13, no. 27, pp. 3523–3562, 2006.

[17] N. Cooper, M. M. Teixeira, J. Warnecke, et al., “A comparison of the inhibitory activity of PDE4 inhibitors on leukocyte PDE4 activity in vitro and cosinophil trafficking in vivo,” British Journal of Pharmacology, vol. 126, no. 8, pp. 1863–1871, 1999.

[18] F. L. van Lent, K. Nabbe, A. B. Blom, et al., “Role of activatory FcγRI and FcγRIII and inhibitory FcγRII in inflammation and cartilage destruction during experimental antigen-induced arthritis,” American Journal of Pathology, vol. 159, no. 6, pp. 2309–2320, 2001.

[19] C. Romay, N. Ledón, and R. González, “Further studies on anti-inflammatory activity of phycocyanin in some animal models of inflammation,” Inflammation Research, vol. 47, no. 8, pp. 334–338, 1998.

[20] C. Jakubzick, E. S. Choi, B. H. Joshi, et al., “Therapeutic attenuation of pulmonary fibrosis via targeting of IL-4 and IL-13 responsive cells,” Journal of Immunology, vol. 171, no. 5, pp. 2684–2693, 2003.

[21] F. A. Meyer, I. Yaron, V. Mashiah, and M. Yaron, “Methotrexate inhibits proliferation but not interleukin 1 stimulated secretory activities of cultured human synovial fibroblasts,” Journal of Rheumatology, vol. 20, no. 2, pp. 238–242, 1993.

[22] N. J. Olsen and L. M. Murray, “Antiproliferative effects of methotrexate on peripheral blood mononuclear cells,” Arthritis & Rheumatism, vol. 32, no. 4, pp. 378–385, 1989.

[23] S. G. Firestein, “Evolving concepts of rheumatoid arthritis,” Nature, vol. 423, no. 6937, pp. 356–361, 2003.

[24] A. Bucht, P. Larsson, L. Weisbrod, et al., “Expression of interferon-gamma (IFN-γ), IL-10, IL-12 and transforming growth factor-beta (TGF-β) mRNA in synovial fluid cells from patients in the early and late phases of rheumatoid arthritis (RA),” Clinical & Experimental Immunology, vol. 103, no. 3, pp. 357–367, 1996.

[25] Y. Morita, M. Yamamura, K. Nishida, et al., “Expression of interleukin-12 in synovial tissue from patients with rheumatoid arthritis,” Arthritis & Rheumatism, vol. 41, no. 2, pp. 306–314, 1998.

[26] F. Puppo, G. Murdaca, M. Ghio, and F. Indiveri, “Emerging biologic drugs for the treatment of rheumatoid arthritis,” Autoimmunity Reviews, vol. 4, no. 8, pp. 537–541, 2005.

[27] E. H. Choy, D. A. Isenberg, T. Garrood, et al., “Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial,” Arthritis & Rheumatism, vol. 46, no. 12, pp. 3143–3150, 2002.

[28] N. Nishimoto, K. Yoshizaki, N. Miyasaka, et al., “Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial,” Arthritis & Rheumatism, vol. 50, no. 6, pp. 1761–1769, 2004.

[29] V. Kouskoff, A.-S. Korganow, V. Duchatelle, C. Degott, C. Benoist, and D. Mathis, “Organ-specific disease provoked by systemic autoimmunity,” Cell, vol. 87, no. 5, pp. 811–822, 1996.

[30] M. Feldmann, F. M. Brennan, and R. N. Maini, “Role of cytokines in rheumatoid arthritis,” Annual Review of Immunology, vol. 14, pp. 397–440, 1996.

[31] D. E. Griswold, E. F. Webb, A. M. Badger, et al., “SB 207499 (AriPlo), a second generation phosphodiesterase 4 inhibitor, reduces tumor necrosis factor α and interleukin-6 production in vivo,” Journal of Pharmacology and Experimental Therapeutics, vol. 287, no. 2, pp. 705–711, 1998.

[32] H.-S. Cha, T. J. Kim, J.-Y. Kim, et al., “Autoantibodies to glucose-6-phosphate isomerase are elevated in the synovial fluid of rheumatoid arthritis patients,” Scandinavian Journal of Rheumatology, vol. 33, no. 3, pp. 179–184, 2004.

[33] M. Schaller, W. Stohl, V. Benoist, S.-M. Tan, L. Johansen, and H.-J. Stüdel, “Patiara with inflammatory arthritic diseases harbor elevated serum and synovial fluid levels of free and immune-complexed glucose-6-phosphate isomerase (G6P),” Biochemical and Biophysical Research Communications, vol. 349, no. 2, pp. 838–845, 2006.

[34] K. Yamaki, X. Li, H. Uchida, et al., “Effects of the phosphodiesterase IV inhibitor rolipram on Th1 and Th2 immune
responses in mice," Journal of Pharmacy and Pharmacology, vol. 56, no. 7, pp. 877–882, 2004.

[35] K. Yamaki, X. Li, M. A. Hossain, et al., “Difference in preventive effects between the phosphodiesterase IV inhibitor rolipram and anti-arthritis drugs on antigen-induced arthritis in mice,” Immunological Investigations, vol. 36, no. 2, pp. 131–145, 2007.

[36] A. Hatzelmann and C. Schudt, “Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor rolumlumast in vitro,” Journal of Pharmacology and Experimental Therapeutics, vol. 297, no. 1, pp. 267–279, 2001.

[37] D. Claveau, S. L. Chen, S. O’Keefe, et al., “Preferential inhibition of T helper 1, but not T helper 2, cytokines in vitro by L-826,141 [4-{2-(3,4-bisdifluromethoxyphenyl)-2-[4-(1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)-phenyl]-ethyl]-3-methylpyridine-1-oxide], a Potent and Selective Phosphodiesterase 4 Inhibitor,” Journal of Pharmacology and Experimental Therapeutics, vol. 310, no. 2, pp. 752–760, 2004.

[38] H. C. Heystek, A.-C. Thierry, P. Soulard, and C. Moulon, “Phosphodiesterase 4 inhibitors reduce human dendritic cell inflammatory cytokine production and Th1-polarizing capacity,” International Immunology, vol. 15, no. 7, pp. 827–835, 2003.

[39] I. B. McInnes and G. Schett, “Cytokines in the pathogenesis of rheumatoid arthritis,” Nature Reviews Immunology, vol. 7, no. 6, pp. 429–442, 2007.